Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...

Cytokinetics, Incorporated’s CYTK share price has surged by 13.20%, which has investors questioning if this is right time to ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ: CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Gilead legal chief, leaves Cytokinetics after 7 months as CLO. His exit comes as the biotech awaits FDA decision on a heart ...

On March 17, analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK ...

The company has plans to continue the go-to-market goals for aficamten in Germany in 2025. Cytokinetics, Incorporated (NASDAQ:CYTK) also aims to expand commercial readiness activities in Europe ...

The company has made good pipeline progress of late. Lead candidate aficamten is under review in the United States for the treatment of obstructive hypertrophic cardiomyopathy. Other pipeline ...

Cytokinetics, specializing in muscle biology-directed therapies, is preparing for potential regulatory approvals of its HCM drug candidate, aficamten, following positive results from clinical trials.